Eversept Partners LP Has $14.76 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

Eversept Partners LP reduced its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 13.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 420,827 shares of the company’s stock after selling 67,765 shares during the quarter. Eversept Partners LP owned approximately 0.37% of NewAmsterdam Pharma worth $14,763,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in NewAmsterdam Pharma in the 1st quarter worth approximately $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock worth $5,898,000 after buying an additional 34,563 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 15.9% during the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after buying an additional 13,629 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of NewAmsterdam Pharma by 33.5% during the second quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock worth $801,000 after buying an additional 11,106 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 12.7% during the second quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock worth $2,427,000 after buying an additional 15,101 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $30.15 on Thursday. The business’s fifty day moving average price is $33.26 and its two-hundred day moving average price is $33.42. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $17.63 and a fifty-two week high of $42.21. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -16.84 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million during the quarter. Research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Analyst Ratings Changes

NAMS has been the subject of a number of research analyst reports. Guggenheim upped their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Finally, Truist Financial assumed coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.60.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.